Disease Prevention

Pioglitazone deters diabetes in women at high risk

Published in Obesity and Diabetes Week, July 7th, 2003

Administering a commonly available drug to lower insulin resistance in women who are at high risk for type 2 diabetes appears to prevent onset of the disease.

Researchers at the Keck School of Medicine of the University of Southern California presented the new findings at the American Diabetes Association's 63rd Annual Scientific Sessions on June 17, 2003, in New Orleans, Louisiana.

The Pioglitazone in Prevention of Diabetes (PIPOD) study tested whether pioglitazone could continue protecting women from diabetes just as troglitazone had done in the researchers' prior study, TRIPOD. Both drugs appear to reduce the demands placed on beta cells, which...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry